Press Release MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism Aug 27
Press Release MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights Aug 6